EGFR and non-small cell lung carcinoma: Inline in the early-stage NSCLC scenario, such as IMPOWERE 010 study, the median disease-free survival (mDFS) was not improved by the adjuvant atezolizumab in the ALK+ subgroup but was numerically elevated in EGFR mutated subgroup [3].